Published in Clin Cancer Res on January 26, 2010
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 2.27
Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC. Eur J Nucl Med Mol Imaging (2015) 1.41
Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging (2011) 1.27
ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology (2016) 1.09
Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE. Eur J Nucl Med Mol Imaging (2016) 1.06
A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging (2011) 1.04
18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in mice. PLoS One (2014) 1.04
Simultaneous hyperpolarized (13)C-pyruvate MRI and (18)F-FDG-PET in cancer (hyperPET): feasibility of a new imaging concept using a clinical PET/MRI scanner. Am J Nucl Med Mol Imaging (2014) 1.02
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) (2015) 0.98
Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med (2013) 0.96
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study. Eur J Nucl Med Mol Imaging (2014) 0.95
Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao Paulo) (2012) 0.90
Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging (2016) 0.89
Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs). Theranostics (2012) 0.88
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 0.87
Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol (2015) 0.83
Update on pancreatic neuroendocrine tumors. Gland Surg (2014) 0.83
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2014) 0.83
Prognostic Value of Volume-Based Metabolic Parameters Measured by (18)F-FDG PET/CT of Pancreatic Neuroendocrine Tumors. Nucl Med Mol Imaging (2014) 0.83
Lesion-based analysis of (18)F-FDG uptake and (111)In-Pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med (2014) 0.82
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev (2015) 0.80
Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor. Eur J Nucl Med Mol Imaging (2014) 0.80
Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours. Ann Transl Med (2015) 0.79
Positron emission tomography scan for a hepatic mass. Hepatology (2010) 0.79
In vivo evaluation of PEGylated (64)Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. Eur J Nucl Med Mol Imaging (2015) 0.79
Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms. Nat Rev Clin Oncol (2016) 0.78
Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest (2014) 0.78
State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am (2016) 0.78
Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice. Cancer Imaging (2012) 0.77
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect (2016) 0.77
Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review. BMC Cancer (2014) 0.77
Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging (2015) 0.77
Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes (2016) 0.76
Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? Eur J Nucl Med Mol Imaging (2015) 0.76
Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions. J Am Coll Surg (2014) 0.76
Nuclear medicine in NET. Wien Med Wochenschr (2012) 0.76
The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics (2017) 0.75
Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach? World J Clin Oncol (2016) 0.75
(18)F-FDG PET/CT Imaging of Primary Hepatic Neuroendocrine Tumor. Asia Ocean J Nucl Med Biol (2015) 0.75
Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology. Cell Mol Gastroenterol Hepatol (2015) 0.75
Gene Expression of Glucose Transporter 1 (GLUT1), Hexokinase 1 and Hexokinase 2 in Gastroenteropancreatic Neuroendocrine Tumors: Correlation with F-18-fluorodeoxyglucose Positron Emission Tomography and Cellular Proliferation. Diagnostics (Basel) (2013) 0.75
High clinical and morphologic response using (90)Y-DOTA-octreotate sequenced with (177)Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2016) 0.75
Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Arch Med Sci (2017) 0.75
Pancreatic Neuroendocrine Tumors: an Update. Indian J Surg (2015) 0.75
Multimodality imaging using proton magnetic resonance spectroscopic imaging and (18)F-fluorodeoxyglucose-positron emission tomography in local prostate cancer. World J Radiol (2017) 0.75
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance. Theranostics (2017) 0.75
The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever.... Eur J Nucl Med Mol Imaging (2014) 0.75
Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. Eur J Nucl Med Mol Imaging (2017) 0.75
Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. Eur J Nucl Med Mol Imaging (2017) 0.75
Preoperative staging of lung cancer with combined PET-CT. N Engl J Med (2009) 7.38
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 3.99
Detection of pulmonary embolism with combined ventilation-perfusion SPECT and low-dose CT: head-to-head comparison with multidetector CT angiography. J Nucl Med (2009) 3.12
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood (2005) 2.92
A classical brown adipose tissue mRNA signature partly overlaps with brite in the supraclavicular region of adult humans. Cell Metab (2013) 2.54
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging (2010) 2.48
Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. Thorax (2010) 2.44
Tumor volume in subcutaneous mouse xenografts measured by microCT is more accurate and reproducible than determined by 18F-FDG-microPET or external caliper. BMC Med Imaging (2008) 2.30
Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica (2006) 1.98
Evaluation of right ventricular volume and function by 2D and 3D echocardiography compared to MRI. Eur J Echocardiogr (2005) 1.96
Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol (2012) 1.93
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology (2012) 1.68
Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail (2005) 1.64
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview. Acta Oncol (2004) 1.62
Gene expression and 18FDG uptake in atherosclerotic carotid plaques. Nucl Med Commun (2010) 1.57
PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer (2006) 1.52
Independent effects of both right and left ventricular function on plasma brain natriuretic peptide. Eur J Heart Fail (2007) 1.51
Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck (2008) 1.49
miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol Cancer (2011) 1.46
Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. Am Heart J (2004) 1.46
Early clinical experience and impact of 18F-FDG PET. Nucl Med Commun (2005) 1.46
HIV infection and arterial inflammation assessed by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET): a prospective cross-sectional study. J Nucl Cardiol (2014) 1.46
Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging (2006) 1.46
Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med (2010) 1.27
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types. Acta Oncol (2004) 1.23
Diagnostic procedures for submucosal tumors in the gastrointestinal tract. World J Gastroenterol (2007) 1.16
Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. Am J Nucl Med Mol Imaging (2013) 1.15
Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours. Acta Oncol (2010) 1.15
MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. Gynecol Oncol (2012) 1.14
Comparison of V/Q SPECT and planar V/Q lung scintigraphy in diagnosing acute pulmonary embolism. Nucl Med Commun (2010) 1.12
The diagnostic value of PET/CT for primary ovarian cancer--a prospective study. Gynecol Oncol (2007) 1.10
The diagnostic and prognostic value of ¹⁸F-FDG PET/CT in the initial assessment of high-grade bone and soft tissue sarcoma. A retrospective study of 89 patients. Eur J Nucl Med Mol Imaging (2012) 1.09
FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function. EMBO J (2011) 1.09
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncol (2014) 1.05
Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med (2012) 1.04
A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist (2012) 1.03
Clinical evaluation of PET image reconstruction using a spatial resolution model. Eur J Radiol (2012) 1.02
Hepatitis C virus infection and risk of coronary artery disease: a systematic review of the literature. Clin Physiol Funct Imaging (2012) 1.02
18FDG PET and ultrasound echolucency in carotid artery plaques. JACC Cardiovasc Imaging (2010) 1.02
Autonomic dysfunction in HIV patients on antiretroviral therapy: studies of heart rate variability. Clin Physiol Funct Imaging (2007) 1.01
18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. Oncologist (2011) 1.00
Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J (2007) 0.99
Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med (2012) 0.99
Changes in lung function of HIV-infected patients: a 4.5-year follow-up study. Clin Physiol Funct Imaging (2012) 0.98
Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica (2011) 0.96
68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol (2011) 0.95
Reduction in coronary and peripheral vasomotor function in patients with HIV after initiation of antiretroviral therapy: a longitudinal study with positron emission tomography and flow-mediated dilation. Nucl Med Commun (2010) 0.95
microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-κB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer (2012) 0.95
Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail (2006) 0.94
PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum (2007) 0.94
When to image carotid plaque inflammation with FDG PET/CT. Nucl Med Commun (2010) 0.94
Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol. PLoS One (2011) 0.93
Utility of planar bone scintigraphy to distinguish benign osteochondromas from malignant chondrosarcomas. Clin Nucl Med (2002) 0.93
(18)F-FDG PET imaging of murine atherosclerosis: association with gene expression of key molecular markers. PLoS One (2012) 0.93
Nasopharyngeal carcinoma. Treatment planning with IMRT and 3D conformal radiotherapy. Acta Oncol (2007) 0.93
First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. Acta Oncol (2011) 0.93
Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake. Hematol Oncol (2006) 0.92
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol (2014) 0.92
The effect of dynamic knee-extension exercise on patellar tendon and quadriceps femoris muscle glucose uptake in humans studied by positron emission tomography. J Appl Physiol (1985) (2005) 0.92
Liver metastases from colorectal cancer: imaging with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography. Abdom Imaging (2007) 0.92
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood (2014) 0.92
New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nucl Med Biol (2012) 0.92
Advanced quantitative echocardiography in arrhythmogenic right ventricular cardiomyopathy. J Am Soc Echocardiogr (2007) 0.91
Nitric oxide and prostaglandins influence local skeletal muscle blood flow during exercise in humans: coupling between local substrate uptake and blood flow. Am J Physiol Regul Integr Comp Physiol (2006) 0.90
Silent ischemic heart disease and pericardial fat volume in HIV-infected patients: a case-control myocardial perfusion scintigraphy study. PLoS One (2013) 0.90
Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case-control study. BMC Infect Dis (2013) 0.89
PET/MRI in cancer patients: first experiences and vision from Copenhagen. MAGMA (2012) 0.89
Review: comparison of PET rubidium-82 with conventional SPECT myocardial perfusion imaging. Clin Physiol Funct Imaging (2013) 0.88
Effects of body mass index and age on N-terminal pro brain natriuretic peptide are associated with glomerular filtration rate in chronic heart failure patients. Clin Chem (2007) 0.88
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol (2007) 0.88
Von Hippel-Lindau disease (vHL). National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J (2013) 0.88
Fever of unknown origin: a retrospective study of 52 cases with evaluation of the diagnostic utility of FDG-PET/CT. Scand J Infect Dis (2011) 0.88
First (18)F-labeled ligand for PET imaging of uPAR: in vivo studies in human prostate cancer xenografts. Nucl Med Biol (2013) 0.87
A prospective randomized comparison of curved array and radial echoendoscopy in patients with esophageal cancer. Gastrointest Endosc (2003) 0.87
Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications. Clin Physiol Funct Imaging (2013) 0.87
Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology (2011) 0.87
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma (2014) 0.87
Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas. ScientificWorldJournal (2012) 0.86
Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiat Oncol (2013) 0.86
ANP and BNP in atrial fibrillation before and after cardioversion--and their relationship to cardiac volume and function. Int J Cardiol (2007) 0.86
Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology (2008) 0.85
SUVmax of 18FDG PET/CT as a predictor of high-risk endometrial cancer patients. Gynecol Oncol (2013) 0.85
Histamine and the regulation of body weight. Neuroendocrinology (2007) 0.85
The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Am Heart J (2007) 0.84
A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med (2013) 0.84
Microvessel density but not neoangiogenesis is associated with 18F-FDG uptake in human atherosclerotic carotid plaques. Mol Imaging Biol (2012) 0.84
Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol (2015) 0.83